ArticleJournal of general internal medicine2025
Flying Blind: How Thorough are IRBs when Assessing Scientific Value?
Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInstitutional Review Boards (IRBs) in the United States play a crucial role in ensuring the ethical conduct of clinical trials, including assessing the scientific merit of studies to justify the risks to participants. However, prior research suggests that many IRBs do not systematically evaluate scientific merit, raising concerns about the approval of low-quality trials.
objectiveTo investigate whether IRBs provide adequate guidance on assessing scientific merit in their Standard Operating Procedures (SOPs) and other relevant materials.
designA systematic pilot investigation of IRB SOPs and related guidance documents from a sample of U.S.-based non-profit institutions.
participantsIRB materials from 35 U.S.-based non-profit institutions selected from the FDA's Bioresearch Monitoring Information System database, representing 39.9% of submissions between 2018 and 2021. Additionally, materials from one U.S.-based for-profit IRB were included.
interventionsNot applicable. MAIN MEASURES: The presence of guidance on 15 dimensions of scientific merit, clustered into four PICO (Population, Intervention, Comparator, Outcome) categories, was assessed by reviewing IRB SOPs and related documents. Evidence of guidance was determined by mention of keywords related to each dimension. KEY
resultsMost IRB materials mentioned basic study elements such as study design (99%), subject recruitment (90%), and intervention justification (97%). However, critical aspects related to study quality, such as bias reduction (53%) and outcome measurement tools (57%), were less frequently mentioned. The least represented dimension was confounder control (10%).
conclusionsIRB guidance materials vary in their coverage of scientific merit dimensions, with significant gaps in areas critical for assessing study quality. Strengthening guidance materials by including comprehensive instructions for all 15 dimensions could improve IRB assessments of scientific merit, thereby enhancing the ethical oversight of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.